Similarly, pharmacologic inhibition of menin-lysine methyltransferase 2A (KMT2A) binding proved to be an effective antileukemic strategy in preclinical models of KMT2A related leukemias [4] and supported clinical trials evaluating menin inhibitors as targeted therapies in acute leukemia [5]. This evidence concerns the gene KMT2A and acute leukemia.